MXCT News and Press, MaxCyte Inc. From 09/02/21

GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the U.S. m...

MaxCyte Signs Clinical and Commercial License with Sana Biotechnology Agreement represents MaxCyte's 14th strategic platform license (SPL) Sana will use MaxCyte's Flow Electroporation® technology and ExPERT™ platform in conjunction with the development of its hyp...